Rocaltrol is a medication with the active ingredient called calcitriol. It is also known by the generic name calcitriol or 1,25-dihydroxyvitamin D3. Rocaltrol is used to treat conditions caused by low levels of calcium in the blood, such as in patients with chronic kidney failure or hypoparathyroidism.
The Rocaltrol price is approximately £1.21 – £1.64 per caps. It depends on the size of the pack and the amount of active ingredient (30 or 360 mcg).
Rocaltrol contains the active ingredient calcitriol, which is the hormonally active form of Vitamin D3. Calcitriol aids in the regulation of calcium levels in the body by increasing calcium absorption in the intestines and promoting the release of calcium from the bone.
Rocaltrol is primarily prescribed to treat conditions such as hypocalcemia and metabolic bone disease in patients undergoing chronic renal dialysis. It is also indicated for patients with hypoparathyroidism where it helps to manage low blood calcium levels. Additionally, it can be used in individuals with chronic kidney disease to address secondary hyperparathyroidism.
The action of Rocaltrol involves increasing the intestinal absorption of calcium and phosphorus. It also promotes reabsorption of calcium in the kidneys and influences the release of calcium from skeletal stores. Consequently, these actions help to normalize the blood calcium levels and ensure proper functioning of the bones and muscles.
Rocaltrol is administered orally, typically in the form of capsules or an oral solution. The dosage may vary based on the medical condition being treated, the severity of hypocalcemia, and the patient’s response to therapy. For adults, initial doses often range between 0.25 mcg to 0.5 mcg per day, with possible adjustments made by the healthcare provider. It is essential for patients to follow their healthcare provider’s instructions closely.
Calcitriol is absorbed well from the gastrointestinal tract following oral administration. Peak plasma concentrations usually occur within 3 to 6 hours after taking the dose. The elimination half-life of calcitriol ranges from 5 to 8 hours in patients with normal renal function, but it may be prolonged in patients with renal impairment. The drug is metabolized in the liver and excreted primarily in the urine and feces.
Rocaltrol can interact with several classes of medications. Concomitant use with thiazide diuretics may increase the risk of hypercalcemia. The efficacy of Rocaltrol may be diminished when used with corticosteroids. Additionally, concurrent use of magnesium-containing antacids may result in hypermagnesemia. Patients should inform their healthcare provider about all medications they are currently taking, including over-the-counter drugs and supplements.
In patients with severe renal impairments, dose adjustments of Rocaltrol may be required due to altered drug clearance. The elderly may be more sensitive to the effects of Rocaltrol, hence a closer monitoring of blood calcium levels is recommended. For pediatric use, the dosage must be cautiously determined by the healthcare provider based on individual requirements and clinical response.
Rocaltrol should be stored at a controlled room temperature, between 20°C to 25°C (68°F to 77°F). It should be kept in a tightly closed container, away from light and moisture. It is essential to keep this medication out of reach from children and pets to prevent accidental ingestion.
Regular monitoring of serum calcium, phosphorus, and parathyroid hormone levels is recommended during Rocaltrol therapy to avoid hypercalcemia and other potential complications. Patients should also undergo periodic renal function tests. Bone mineral density assessments may be required for long-term users, especially in those with underlying bone disorders.
Rocaltrol is contraindicated in patients with hypercalcemia or evidence of vitamin D toxicity. It should not be used in individuals with known hypersensitivity to calcitriol or any of its excipients. The use of Rocaltrol in patients with malabsorption syndromes necessitates caution due to the varying degrees of intestinal absorption of the drug.
There is limited data on the use of Rocaltrol during pregnancy. Animal studies have shown that calcitriol may cause potential risks to the fetus. Therefore, it is classified as a pregnancy category C drug. The decision to use Rocaltrol in pregnant women should only be made if the potential benefit justifies the potential risk to the fetus.
Calcitriol is excreted into human milk. Due to the potential for serious adverse reactions in breastfed infants, a decision should be made whether to discontinue nursing or discontinue Rocaltrol, taking into account the importance of the drug to the mother. The healthcare provider may offer alternative treatments if needed.
Patients should be counseled to adhere strictly to their prescribed dosage and schedule. They should be made aware of the signs and symptoms of hypercalcemia, such as nausea, vomiting, anorexia, weakness, and confusion, and advised to seek medical attention if these occur. Dietary modifications, specifically regarding calcium and vitamin D intake, should be discussed with a healthcare professional.
If a dose of Rocaltrol is missed, the patient should take it as soon as they remember unless it is almost time for the next dose. In such a case, the missed dose should be skipped, and the next dose should be taken at the regular time. Double doses should be avoided to prevent potential overdose and associated complications.
In the event of an overdose, symptoms such as hypercalcemia, dehydration, polyuria, and hypertension may occur. Immediate medical attention is essential. Supportive measures include discontinuation of Rocaltrol, correction of electrolyte imbalances, and administration of fluids. Hemodialysis may be required in severe cases.